TRACK-CF prospective cohort study: Understanding early cystic fibrosis lung disease.

Steinke, Eva; Sommerburg, Olaf; Graeber, Simon Y; Joachim, Cornelia; Labitzke, Christiane; Nissen, Gyde; Ricklefs, Isabell; Rudolf, Isa; Kopp, Matthias V; Dittrich, Anna-Maria; Mall, Marcus A; Stahl, Mirjam (2022). TRACK-CF prospective cohort study: Understanding early cystic fibrosis lung disease. Frontiers in medicine, 9(1034290), p. 1034290. Frontiers 10.3389/fmed.2022.1034290

Preview

Text fmed-09-1034290.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (5MB) | Preview

BACKGROUND

Lung disease as major cause for morbidity in patients with cystic fibrosis (CF) starts early in life. Its large phenotypic heterogeneity is partially explained by the genotype but other contributing factors are not well delineated. The close relationship between mucus, inflammation and infection, drives morpho-functional alterations already early in pediatric CF disease, The TRACK-CF cohort has been established to gain insight to disease onset and progression, assessed by lung function testing and imaging to capture morpho-functional changes and to associate these with risk and protective factors, which contribute to the variation of the CF lung disease progression.

METHODS AND DESIGN

TRACK-CF is a prospective, longitudinal, observational cohort study following patients with CF from newborn screening or clinical diagnosis throughout childhood. The study protocol includes monthly telephone interviews, quarterly visits with microbiological sampling and multiple-breath washout and as well as a yearly chest magnetic resonance imaging. A parallel biobank has been set up to enable the translation from the deeply phenotyped cohort to the validation of relevant biomarkers. The main goal is to determine influencing factors by the combined analysis of clinical information and biomaterials. Primary endpoints are the lung clearance index by multiple breath washout and semi-quantitative magnetic resonance imaging scores. The frequency of pulmonary exacerbations, infection with pro-inflammatory pathogens and anthropometric data are defined as secondary endpoints.

DISCUSSION

This extensive cohort includes children after diagnosis with comprehensive monitoring throughout childhood. The unique composition and the use of validated, sensitive methods with the attached biobank bears the potential to decisively advance the understanding of early CF lung disease.

ETHICS AND TRIAL REGISTRATION

The study protocol was approved by the Ethics Committees of the University of Heidelberg (approval S-211/2011) and each participating site and is registered at clinicaltrials.gov (NCT02270476).

Interest & Impact

Downloads

14 since deposited on 25 Jan 2023
14 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item